<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622739</url>
  </required_header>
  <id_info>
    <org_study_id>SaxenaZiprasidone</org_study_id>
    <nct_id>NCT00622739</nct_id>
  </id_info>
  <brief_title>Ziprasidone in Pediatric Bipolar Disorder</brief_title>
  <official_title>Ziprasidone in Pediatric Bipolar Disorder: a 6-week, Open-label Comparison of Rapid vs. Slow Dose Titration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Medical Center Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6 week, open-label, blinded-rater, randomized, controlled, pilot study designed to
      determine the dosing, safety and efficacy of ziprasidone in the treatment of pediatric
      bipolar disorder (PBD). In this pilot study we are comparing the efficacy of rapid versus
      slow dose titration of ziprasidone in PBD. The investigators hypothesize that subjects on
      ziprasidone monotherapy will have a reduction in manic symptoms. Also, the investigators
      hypothesize that slower titration of ziprasidone will result in lesser side effects which
      will assist in medication compliance as measured by patient report and pill count.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll approximately 60 children and adolescents aged 10-17 years who have
      been diagnosed with bipolar disorder. Their participation will last about 8 weeks (2 weeks of
      screening and 6 weeks of medication management) and enrollment will last for two years. After
      the screening period, all subjects who meet inclusion/exclusion criteria will be randomized
      to either rapid or slow dose titration of ziprasidone. Subjects in the rapid titration group
      will reach their maximum dose of study drug over 2 weeks, subjects in the slow titration
      group over 4 weeks. The study doctor may deviate from the dosing schedule if clinically
      indicated. The primary data analysis of this pilot study will examine the effect of rapid-
      versus slow-dose titration of ziprasidone on manic symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Young Mania Rating Scale (YMRS)</measure>
    <time_frame>6 weeks of treatment</time_frame>
    <description>The Young Mania Rating Scale (YMRS) is a measure of the severity of manic symptoms. The scores on the scale range from 0-56. A score of more than or equal to 14 was the cut off for inclusion into this study. A higher score denotes increased severity of manic symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions (CGI) Scale</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAFTEE (Side Effects Rating Scale)</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AIMS (Abnormal Involuntary Movement Scale)</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Depression Rating Scale</measure>
    <time_frame>Weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>ziprasidone rapid dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapid Dose Titration Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ziprasidone slow dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Slow Dose Titration Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
    <arm_group_label>ziprasidone rapid dose</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
    <arm_group_label>ziprasidone slow dose</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients aged 10-17 years

          -  Currently meet Diagnostic and Statistical Manual of Mental Disorders IV-Text Revision
             (DSM-IV-TR) criteria for bipolar disorder, type I, II or Not Otherwise Specified (NOS)
             as determined by the Schedule for Affective Disorders and Schizophrenia
             -Present/Lifetime (Kiddie-SADS-PL)

          -  Experiencing manic, hypomanic or mixed states as determined by clinical diagnosis and
             Kiddie- Young Mania rating scale (K-YMRS) equal to or more than 14

          -  General good health as determined by medical history, physical examination, and
             laboratory evaluations

          -  Female adolescents, if sexually active, must practice birth control methods approved
             by the primary investigator

          -  Ability to swallow tablets

          -  Subject's parent or guardian must be fully capable of monitoring the subject's disease
             process and compliance to treatment

          -  Parent(s) or legal guardian(s) must read and sign the informed consent form after the
             nature of the study has been fully explained and assent must be obtained from
             subjects.

        Exclusion Criteria:

          -  Have a lifetime DSM-IV-TR Axis I disorder diagnosis of autistic disorder,
             schizophrenia, schizoaffective disorder, or other psychotic disorders

          -  DSM-IV-TR diagnosis of alcohol or substance abuse or dependence within the past 6
             months

          -  Serious or unstable medical or neurological conditions which require concomitant
             medications

          -  Judged by the principal investigator (PI) to be acutely suicidal or homicidal, or at
             imminent risk of injuring self or others or causing significant damage to
             propertyâ€”i.e., subject needs to be in an inpatient facility

          -  Known or suspected intelligence quotient (IQ) less than 70

          -  Have a DSM-IV-TR diagnosis of anorexia and/or bulimia at the time of screening or
             within the last six months

          -  Female who is pregnant or nursing

          -  Subjects with a history of syncopal episodes (sudden loss of consciousness with loss
             of postural tone and not preceded by a pre-syncopal phase) or unexplained loss of
             consciousness

          -  Subjects with a history of significant cardiovascular disease or significant
             concurrent cardiovascular disease, including uncontrolled hypertension, hypotension,
             congestive heart failure or congenital heart disease

          -  Subjects with a history of cardiac arrhythmias, conduction abnormalities or known
             personal history or corrected QT prolongation (including congenital long QT syndrome)

          -  Subjects with a known genetic risk for QT syndrome determined by family history in
             first degree relatives

          -  Subjects taking any medications known to interact with ziprasidone or subjects taking
             any medications which have been consistently observed to prolong the QT interval

          -  Subjects with a clinically significant ECG abnormality at screening

          -  Subjects with persistent QTc (Fridericia) * 460 msec at screening

          -  Screening laboratory values outside the normal range and judged to be clinically
             significant by the investigator

          -  Patients and families that are Spanish speaking only will be excluded from the study
             as some instruments used in the study have not been validated in Spanish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirti Saxena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <results_first_submitted>March 12, 2014</results_first_submitted>
  <results_first_submitted_qc>June 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2014</results_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Kirti Saxena</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ziprasidone Rapid Dose Group</title>
          <description>Rapid Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
        </group>
        <group group_id="P2">
          <title>Ziprasidone Slow Dose Group</title>
          <description>Slow Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ziprasidone Rapid Dose Group</title>
          <description>Rapid Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
        </group>
        <group group_id="B2">
          <title>Ziprasidone Slow Dose Group</title>
          <description>Slow Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.53" spread="2.62"/>
                    <measurement group_id="B2" value="13.38" spread="2.50"/>
                    <measurement group_id="B3" value="13.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Young Mania Rating Scale (YMRS)</title>
        <description>The Young Mania Rating Scale (YMRS) is a measure of the severity of manic symptoms. The scores on the scale range from 0-56. A score of more than or equal to 14 was the cut off for inclusion into this study. A higher score denotes increased severity of manic symptoms.</description>
        <time_frame>6 weeks of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone Rapid Dose Group</title>
            <description>Rapid Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
          </group>
          <group group_id="O2">
            <title>Ziprasidone Slow Dose Group</title>
            <description>Slow Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale (YMRS)</title>
          <description>The Young Mania Rating Scale (YMRS) is a measure of the severity of manic symptoms. The scores on the scale range from 0-56. A score of more than or equal to 14 was the cut off for inclusion into this study. A higher score denotes increased severity of manic symptoms.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.70" spread="1.41"/>
                    <measurement group_id="O2" value="12.57" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impressions (CGI) Scale</title>
        <time_frame>Weekly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAFTEE (Side Effects Rating Scale)</title>
        <time_frame>Weekly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AIMS (Abnormal Involuntary Movement Scale)</title>
        <time_frame>Weekly</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Children's Depression Rating Scale</title>
        <time_frame>Weekly</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone Rapid Dose Group</title>
          <description>Rapid Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
        </group>
        <group group_id="E2">
          <title>Ziprasidone Slow Dose Group</title>
          <description>Slow Dose Titration Group
Ziprasidone: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dystonic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>worsening of mood and inadequate response to medicaiton</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kirti Saxena</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-822-4065</phone>
      <email>kxsaxen1@texaschildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

